drugset
drugset / Trial / NCT06921044

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

NCT06921044 ↗

Phase 2 Not yet recruiting 33 enrolled Xiaohui He CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Research purpose： To evaluate the efficacy and safety of R-mini-MCOP in first-line treatment of primary treatment of diffuse large B-cell lymphoma (DLBCL) in elderly patients Experimental design： Single-arm, multicenter, prospective study

Timeline

Start
2025-04-16
Primary completion
2026-02-01
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 6 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 8 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 10 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 400 mg/m2 Intravenous
Background Prednisone Other / unclassified 40 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1 mg Intravenous

Indications

diffuse large B-cell lymphoma